LICENSE AGREEMENT by and among COHERUS BIOSCIENCES, INC., BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE CORPORATION, AND BAXTER HEALTHCARE SA dated August 30, 2013License Agreement • September 25th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
The following general matters related to the subject matter of this Agreement may be disclosed by Coherus to potential investors, collaboration partners and underwriters, on a non-confidential basis and without the prior written consent of Licensee:
SELEXIS COMMERCIAL LICENSE AGREEMENT ENTERED INTO WITH BIOGENERICS, INC.License Agreement • September 25th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Commercial License Agreement (the “Agreement”) is made effective on April 8, 2011 (the “Effective Date”), by and between SELEXIS SA, 18 chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland SA (“Selexis”) and BIOGENERICS, INC. 555 Bryant Street, Ste 266, Palo Alto, CA 94301 (“COMPANY”).
LICENSE AGREEMENT by and between BIOGENERICS, INC. and DAIICHI SANKYO COMPANY, LIMITED dated January 23rd, 2012License Agreement • September 25th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
CONFIDENTIALCoherus BioSciences, Inc. • September 25th, 2014 • Biological products, (no disgnostic substances)
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
DISTRIBUTION AGREEMENTDistribution Agreement • September 25th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
THIS DISTRIBUTION AGREEMENT (the “Agreement”) is made and entered into as of December 26, 2012 (the “Effective Date”) between COHERUS BIOSCIENCES, INC., a Delaware corporation with a principal place of business at 201 Redwood Shores Parkway, Suite 200, Redwood City, California 94065, United States of America (“Coherus”), and OROX PHARMACEUTICALS B.V., a Caraçao company with a principal place of business at Schottegatweg Oost 10, unit 1A1, Curaçao (“Distributor”). Coherus and Distributor are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT #4 TO TASK ORDER #13 COHERUS Project Number: CHS-0214-02 MEDPACE Project Number: ETA302Coherus BioSciences, Inc. • September 25th, 2014 • Biological products, (no disgnostic substances)
MASTER SERVICES AGREEMENTMaster Services Agreement • September 25th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • Delaware
This Master Services Agreement (the “Agreement”), dated as of January 23, 2012 (the “Effective Date”), is between Medpace, Inc., an Ohio Corporation with a principal place of business at 5375 Medpace Way, Cincinnati, OH 45227 (“MEDPACE”) and BioGenerics, Inc., a Delaware Corporation with a principal place of business at 201 Redwood Shores Parkway, Suite 200, Redwood City, CA 94065 (“SPONSOR”). MEDPACE and SPONSOR are sometimes referred to herein individually as a “Party” and together as the “Parties”.
AMENDMENT #2 TO TASK ORDER #13 COHERUS Project Number: CHS0214-02 MEDPACE Project Number: ETA302Coherus BioSciences, Inc. • September 25th, 2014 • Biological products, (no disgnostic substances)
This Amendment #2 (“Amendment #2”) to Task Order #13 effective as of 18 October 2013 (“Task Order”), is by and between Coherus Bioscience, Inc., a Delaware corporation with its principal place of business at 201 Redwood Shores Parkway, Suite 200, Redwood City, CA 94065 (“Sponsor”), and Medpace, Inc., with its principal place of business at 5375 Medpace Way, Cincinnati, Ohio 45227 (“Medpace”). This Amendment #2 shall be effective 21 May 2014.
CONFIDENTIAL NON-EXCLUSIVE LICENSE AGREEMENT [“Cabilly Patents”]Non-Exclusive License Agreement • September 25th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • California
This Non-Exclusive License Agreement (“Agreement”) is effective as of July 10, 2013 (“Effective Date”) by and between Genentech, Inc., a corporation having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (hereinafter “Genentech”) and Coherus Biosciences, Inc., a corporation having its principal place of business at 201 Redwood Shores Parkway, Suite 200, Redwood City, CA 94065 (hereinafter “Coherus”).
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • September 25th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT (this “Amendment”) is made and entered into as of this 7th day of February, 2014 (the “Effective Date”) by and among Coherus Biosciences, Inc., a Delaware corporation with a principal place of business at 201 Redwood Shores Parkway, Suite 200, Redwood City, California 94065, United States of America (“Coherus”), on the one hand, and Baxter International, Inc., a Delaware corporation with a principal place of business at 1 Baxter Parkway, Deerfield, IL 60015, United States of America (“BII”), Baxter Healthcare SA, a Swiss corporation with a principal place of business at Postfach 8010 Zurich, Switzerland (“BHSA”) and Baxter Healthcare Corporation, a Delaware corporation with a principal place of business at 1 Baxter Parkway, Deerfield, IL 60015, United States of America (“BHC” and, together with BII and BHSA, “Baxter’’), on the other hand to amend the terms of that certain License Agreement between Coherus and Baxter dated August 30, 2013 (the “License Agreement”).
AMENDMENT #3 TO TASK ORDER #13 COHERUS Project Number: CHS0214-02 MEDPACE Project Number: ETA302Coherus BioSciences, Inc. • September 25th, 2014 • Biological products, (no disgnostic substances)
This Amendment #3 (“Amendment #3”) to Task Order #13 effective as of 18 October 2013 (“Task Order”), is by and between Coherus Bioscience, Inc., a Delaware corporation with its principal place of business at 201 Redwood Shores Parkway, Suite 200 Redwood City, CA 94065 (“Sponsor”), and Medpace, Inc., with its principal place of business at 5375 Medpace Way, Cincinnati, Ohio 45227 (“Medpace”). This Amendment #3 shall be effective 30 May 2014.
COHERUS BIOSCIENCES INC.Equity Incentive Plan • September 25th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • Delaware
Pursuant to its 2010 Equity Incentive Plan, as amended from time to time (the “Plan”), Coherus BioSciences Inc., a Delaware corporation (the “Company”), hereby grants to the Optionee listed below (“Optionee”), an option to purchase the number of shares of the Company’s Common Stock set forth below, subject to the terms and conditions of the Plan and this Stock Option Agreement (this “Option Agreement”). Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Option Agreement.
THIRD AMENDMENTCoherus BioSciences, Inc. • September 25th, 2014 • Biological products, (no disgnostic substances)
THIS THIRD AMENDMENT (this “Amendment”) is made and entered into as of February 4, 2014, by and between CA-TOWERS AT SHORES CENTER LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and COHERUS BIOSCIENCES, INC., a Delaware corporation (“Tenant”).
FIRST AMENDMENTFirst Amendment • September 25th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT (this “Amendment”) is made and entered into as of May 17, 2012, by and between CA-TOWERS AT SHORES CENTER LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and COHERUS BIOSCIENCE, INC., a Delaware corporation (“Tenant”).
FOURTH AMENDMENTFourth Amendment • September 25th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
THIS FOURTH AMENDMENT (this “Fourth Amendment”) is made and entered into as of May 1, 2014, by and between CA-TOWERS AT SHORES CENTER LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and COHERUS BIOSCIENCES, INC., a Delaware corporation (“Tenant”).
